

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 15, No. 14

July 29th, 2016

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association and membership news*. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- CMS's CY2017 proposed MPFS
- Prolonged pump infusions
- MACRA updates and resources
- ANCO's 2016 Professional Education Meeting
- ANCO's ASCO Highlights 2016

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members.

The next regular *ANCO FAX News* will be published on August 19th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- ☐ Physician Members
- ☐ Nurses & Office Managers
- ☐ Office Staff
- ☐ Colleagues & Representatives

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

CMS released the proposed CY2017 *Medicare Physician Fee Schedule* (MPFS) at www.federalregister.gov/articles/2016/07/15/2016-16097/medicare-program-payment-policies-under-the-physician-fee-schedule-medicare-advantage-pricing-data. It estimates that in CY2017 reimbursement for the hematology/oncology specialty is set to increase by 2%, though the impact on individual practices will depend on the mix of services provided. ASCO is evaluating the proposed MPFS in detail. Read ASCO's initial summary of the proposed CY2017 MPFS at www.asco.org/advocacy-policy/asco-in-action/proposed-2017-medicare-physician-fee-schedule-rule-released; read ACCC's summary analysis at mynetwork.accc-cancer.org/viewdocument/2017-cms-opps-and-pf; read ASH's www.hematology.org/Advocacy/Policy-News/2016/6440.aspx. **Register and listen to Bobbi Buell's webinar entitled *Medicare Proposed Rule for 2017 and Other Issues*** (August 10, 9AM PT, cc.readytalk.com/registration/#/?meeting=wqpr4n887l5d&campaign=mz6m9ppz83ro; September 2, 9AM PT, cc.readytalk.com/registration/#/?meeting=n0h4jpuqikvp&campaign=bztndtjw6kox). Read Bobbi's analysis at www.anco-online.org/BBMPFS2017Analysis.pdf.

CMS recently provided additional clarification to MACs and providers regarding reimbursement for prolonged drug and biological infusions that are started in the office and that are associated with care that is billed incident to a physician service using an external pump. Go to MLN Matters SE1609 at www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/SE1609.pdf for detailed information.

CMS testified before the *Senate Finance Committee* that the *Administration* would adjust its plan to reduce Medicare payments for many prescription drugs—but those assurances did not fully allay deep concerns from the *Senators*. CMS indicated that the *Administration* would probably go ahead with its proposal in some form and pledged that it would try to prevent any harm to patients. At the same hearing, ASCO voiced its strong opposition to CMS's plans. Read ASCO's testimony at www.asco.org/sites/new-www.asco.org/files/content-files/blog-release/documents/June-2016-ASCO-Finance-Part-B-Hearing-Statement.pdf?et_cid=38017965&et_rid=801330592&linkid=comments. ASCO supports HR5122, legislation that would halt CMS from implementing the CMS Medicare Part B drug reimbursement experiment and helps to keep the pressure on the *Administration* to withdraw or substantially change the experiment, and urges the *House* to pass it in a timely manner. Please ask your *Representative* to co-sponsor HR5122 today by visiting cqrcengage.com/asco/.

CMS is considering moving the start date for select provisions and using shorter baseline reporting periods for MACRA based on stakeholder feedback. As proposed, MACRA redefines how Medicare will reimburse oncologists for care they provide starting in January 2019. However, because evaluation begins in less than six months (i.e., 2017), it is imperative that oncologists understand and prepare for this reimbursement change now. Medicare intends to pay each provider a different fee based on their value and performance. Providers will choose one of two pathways. Providers choosing the *Merit-Based Incentive Payment System* (MIPS) will be paid higher or lower fees for each service provided based on their Composite Performance Score. Providers choosing the *Advanced Alternative Payment Model* (APM) will participate in risk-based programs and receive a 5% bonus. **Services provided in 2017 will form the basis for payments in 2019** and the actions you take starting in January 2017 will result in a reduction of up to 4% or increase of up to 22% in your Medicare revenue in 2019. Go to www.asco.org/practice-guidelines/practice-management-issues/medicare-program/macra for more information, including new ASCO MACRA resources and educational events. Download ASCO's step-by-step guide to preparing for MACRA at

online.org/ASCOMACRAPrep.pdf. Read ASCO's comments on the proposed MACRA regulations at www.asco.org/advocacy-policy/asco-in-action/asco-submits-comments-proposed-macra-implementation-rule. **Listen to ACCC's webinar on MACRA** at attendee.gotowebinar.com/recording/viewRecording/2308644939852908546/4288900566134237187/execdir@anco-online.org. **Read ACCC's comments on the proposed MACRA regulations** at www.accc-cancer.org/advocacy/pdf/2016-ACCC-Comment-Letter-to-CMS-on-Proposed-MACRA-Rule.pdf. **Read COA's comments on the proposed MACRA regulations** at www.communityoncology.org/wp-content/uploads/2016/06/COA_CMS_MACRA_5517PR_Comment_Letter_FINAL.pdf. **Read Bobbi Buell's analysis of the MACRA proposal** at www.anco-online.org/BBMacraAnalysis.pdf.

MACRA encourages the development of alternatives to the current Medicare fee-for-service payment system as a means to achieve higher quality and more affordable care. ASCO believes that its *Patient-Centered Oncology Payment* (PCOP) model meets MACRA's definition of an alternative payment model (APM) and will actively advance PCOP as a certified APM. ASCO is offering practices a unique opportunity to test PCOP and will provide tools and assistance in modeling data to help practices be successful. To learn more about PCOP, please go to www.asco.org/advocacy-policy/policies-positions-guidance/coverage-reimbursement/physician-payment-reform.

CMS announced the start of the *Oncology Care Model* (OCM) on June 29th along with the long awaited list of practices that will be participating (including several ANCO practices). The OCM is an alternative payment model that aims to provide higher quality, more highly coordinated oncology care, while lowering overall costs to Medicare. The practices participating in the OCM have committed to providing enhanced services to Medicare beneficiaries, such as care coordination and navigation, and to using national treatment guidelines for care. For more information, please visit innovation.cms.gov/initiatives/Oncology-Care/. ACCC and COA have initiated OCM support networks; go to www.accc-cancer.org/advocacy/OCM-ResourceCenter.asp or contact OCMSupport@COAcancer.org, respectively.

CMA, MOASC, and State Legislative & Regulatory Issues

On July 1st, a new law (SB137) took effect that requires health plans to ensure that physician directories are accurate and up-to-date. The new law also requires physicians to do their part in keeping this information up-to-date. Specifically, the law requires providers to notify payors within five business days if they are no longer accepting new patients or, alternatively, if they were previously not accepting new patients and are now open to new patients. SB137 also requires physicians to respond to plan and insurer notifications regarding the accuracy of their provider directory information, either by confirming the information is correct or by updating demographic information as appropriate. CMA has published a new resource to help physicians comply with the new directory accuracy law entitled *What Physicians Need to Know to Avoid Penalties Under the New Provider Directory Accuracy Law* and it is available online at www.cmanet.org/resource-library/detail/?item=what-physicians-need-to-know-to-avoid.

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's Center for Economic Services that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe. The July 2016 edition includes:

- CMA publishes guide on new provider directory accuracy law
- Updated payor profiles now available
- United Healthcare extends clinical data submission deadline to September 2
- DMHC IMR/complaint webinar now available
- CMA medical legal library updated for 2016
- California Insurance Commissioner urges DOJ to block Anthem/Cigna merger
- Have you registered for CURES?
- Medi-Cal to reimburse providers for advanced care planning

- The Coding Corner: How coding guidelines define new vs established patients

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) Medicare Administrative Contractor (MAC). Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—Physician Fee Schedule: Proposed CY2017 Changes; Hospital and ASC: Proposed OPPS Changes for CY2017; New Hospice Report Available July 17; Clinical Laboratory Fee Schedule Resources; HIPAA Administrative Simplification Enforcement and Testing Tool; Hospice Quality Reporting: Reconsideration Period Ends Soon; SNF Readmission Measure: Top 10 Things You Should Know; New Payment Models and Rewards for Better Care at Lower Cost; SNF Quarterly Reports Available through Nursing Home Compare; SNF QRP: Requirements for the FY2018 Reporting Year Fact Sheet Available
- Events*—PQRS Feedback Reports and Informal Review Process for Program Year 2015 Results Call-August 10; SNF Quality Reporting Program Provider Training-August 24
- Claims, Pricers, and Codes*—July 2016 OPPS Pricer File Update
- Publications*—Medicare Billing Certificate Programs for Part A and Part B Providers WBT-Revised; Complying with Medicare Signature Requirements Fact Sheet-Revised; Medicare Enrollment Guidelines for Ordering/Referring Providers Fact Sheet-Reminder; Avoiding Medicare Fraud & Abuse: A Roadmap for Physicians Booklet-Revised; How to Use the National Correct Coding Initiative Tools Booklet-Revised; Protecting Patient Personal Health Information MLN Matters Article-New; SNF Quality Reporting Program Call: Audio Recording and Transcript-New; SNF Billing Reference Fact Sheet-Reminder

- Prompt Payment Interest Rate-July 2016 Update
- Stem Cell Transplantation for Multiple Myeloma, Myelofibrosis, and Sickle Cell Disease, and Myelodysplastic Syndromes-Revised CR9620
- Chemotherapy Administration-R2-Revised
- Flow Cytometry LCD-R4
- Self-Administered Drug Exclusion List-R7
- Computed Tomography, 70450-Widespread Service Specific Targeted Review Notification
- MLN Connects eNews-July 21, 2016
- Correction of Remark Code Information CR9641
- Initial Hospital Care, 99223-Widespread Service Specific Targeted Review Notification
- RARC, CARC, MREP and PC Print Update CR9695
- New Waived Tests-Revised CR9687
- CCI Edits, Version 22.3, Effective October 1, 2016-Quarterly Update CR9725
- Protecting Patient PHI SE1616
- Revalidation Due Dates, Upcoming Deactivations and Pend Status

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

***Noridian/JEMAC's* MAC Satisfaction Indicator Survey is now available online for providers to complete.** This survey should only take about 10 minutes of your time and helps *Noridian/JEMAC* understand how to better service you. Complete the *Survey* at med.noridianmedicare.com/web/jeb/article-detail/-/view/10525/evaluate-our-services-in-10-minutes.

***Noridian/JEMAC* reports that only 19% of physicians have responded to the most recent revalidation notices.** It has resumed its regular revalidation cycle and encourages all providers to learn about their revalidation requirements at med.noridianmedicare.com/web/jeb/enrollment/revalidation.

Subscribe today to receive the DHCS/Medi-Cal

Subscription Service (MCSS) via e-mail. The MCSS is a free service that can help keep you up-to-date on the latest DHCS/MediCal news. Go to the MCSS Subscriber Form (files.medi-cal.ca.gov/pubsdoco/mcss/mcss.asp) to subscribe.

A list of DHCS/MediCal webinars is at <https://learn.medi-cal.ca.gov>.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's 2016

Professional Education Meeting

ANCO will host its 2016 professional education meeting on August 3rd at *The Claremont Resort*. An announcement with the agenda and faculty was distributed in early June. The agenda includes *MACRA—What It Is and How Oncology Practices Can Prepare; Managing Oncology within Medicare; California's End of Life Option Act; and, An ANCO Practice Atlas—Who We Are, What We Are Doing in Our Practices, and How This Compares to Other Oncology Practices*. The faculty will be Sybil Green, JD, RPh, *Director, Coverage and Reimbursement, ASCO*; Arthur Lurvey, MD, FACP, FACE, *Medicare Contractor Medical Director, Noridian/JEMAC*; Shirley Otis-Green, MSW, ACSW, LCSW, OSW-C, *Clinical Director of Consulting Services, Coalition for Compassionate Care of California*; and, Elaine L. Towle, CMPE, *Director, Analysis and Consulting Services, Clinical Affairs Department, ASCO*. Download the meeting announcement and registration form at www.anco-online.org/ProfEduc2016.pdf.

ANCO's ASCO Highlights 2016

ANCO's *ASCO Highlights 2016* will take place on Saturday, August 27th at *The Claremont Resort* in Oakland. Faculty from *Stanford University*, the *University of California, Davis*, and the *University of California, San Francisco* will summarize the research and treatment advances reported at *ASCO's Annual Meeting*. A meeting announcement and registration form was distributed in late June. Download the meeting announcement and registration form at www.anco-online.org/ASCOHL2016.pdf.

Additional Education Meetings

Other meetings of possible interest to ANCO member practices are:

August 4-6th

17th Annual International Lung Cancer Congress
Physicians' Education Resource
Huntington Beach
(www.gotoper.com/conferences/ilc/meetings/17th-International-Lung-Cancer-Congress; use code L16ANCO for the ANCO member discount)

August 12-13th

Best of ASCO
American Society of Clinical Oncology
San Diego
(west-bo.a.sco.org)

August 23rd

For Health Care Professionals: Care Coordination for Older Mem Living with Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

September 9-10th

Palliative Care in Oncology Symposium: Patient-Centered Care Across the Cancer Continuum
American Society of Clinical Oncology
San Francisco
(pallonc.org)

September 10th

1st Annual Symposium on Integrating Immune Therapy & Targeted Therapy into Standards of Care for Solid & Hematologic Malignancies
Biomedical Learning Institute
San Francisco
(www.bmli.com/live/immune/registration.php?x=628c)

September 12th

Preventing Chemotherapy Induced Nausea and Vomiting
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

September 16-17th

2016 ASH Meeting on Hematologic Malignancies
American Society of Hematology
Chicago
(www.hematology.org/Malignancies/)

September 20th

Update on Advanced Ovarian Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

September 21st-22nd

ASCO Advocacy Summit 2016—Lead, Engage, Influence

American Society of Clinical Oncology
Washington, D.C.

(www.asco.org/advocacy/2016-advocacy-summit-capitol-hill)

September 23rd

Are You Ready for MACRA? Tools and Resources to Help You Prepare

American Society of Clinical Oncology
Alexandria, VA

(www.surveymonkey.com/r/S652SG8)

September 30th

ICLIO National Conference: Immuno-Oncology—There's More to Discover

ACCC's Institute for Clinical Immuno-Oncology
Philadelphia

(accc-iclio.org/events/iclio-2nd-national-conference/)

October 19th-21st

ACCC 33rd National Oncology Conference: The How-To Conference for the Cancer Care Team

Association of Community Cancer Centers
St. Louis

(www.accc-cancer.org/meetings/NOC2016.asp)

October 30th-November 2nd

2016 Annual Conference

Medical Group Management Association
San Francisco

(www.mgma.com/annual-conference/why-attend)

December 3rd-6th

58th ASH Annual Meeting & Exposition

American Society of Hematology
San Diego

(www.hematology.org/Annual-Meeting/)

February 9-12th

Practical Recommendations in Immuno & Molecular Oncology (PRIMO)

Maui, Hawaii

(www.primomeeting.org)

April 20th-22nd

Cancer Metastasis through the Lymphovascular System: Biology & Treatment—7th International Symposium

Sentinel Node Oncology Foundation
San Francisco

(www.cancermetastasis.org)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors teleconference is scheduled for August 18th**. Please call José Luis González, ANCO Executive Director, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

Applications for ASCO's *Leadership Development Program* are now open and must be received by **September 23rd**. Participants in this year-long *Leadership Program* will gain extensive exposure to the roles and mission of ASCO, its *Leadership*, and the *Society's* powerful place in developing the future of cancer care, providing both an orientation to ASCO as well as as leadership training skills to newer members of the *Society*. Applicants must have completed their final subspecialty training between 2007 and 2012. To learn more about the *Program*, please visit www.asco.org/leadership.

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks

Annadel Medical Group/St Joseph's Heritage Healthcare, California Cancer Associates for Research and Excellence, Diablo Valley Oncology & Hematology Medical Group, EPIC Care, Pacific Cancer Care, Palo Alto Medical Foundation, and Valley Medical Oncology Consultants for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Alexion Pharmaceuticals • AMGEN
ARIAD Pharmaceuticals • Astellas Oncology
AstraZeneca • Bayer Healthcare Pharmaceuticals
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Dendreon • Eisai • Foundation Medicine
Genoptix Medical Laboratory
GenPath Oncology • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Infinity Pharmaceuticals
Ipsen Biopharmaceuticals
Janssen Oncology • Jazz Pharmaceuticals
Lilly Oncology • Merrimack Pharmaceuticals
Medivation • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pharmacyclics • Prometheus Laboratories, Inc.
Sandoz Biopharmaceuticals • Sanofi Genzyme
Seattle Genetics • Taiho Oncology
Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *AbbVie, ARIAD Pharmaceuticals, Clovis Oncology, GenPath Oncology, Guardant Health, Heron Therapeutics, Infinity Pharmaceuticals, Ipsen Pharmaceuticals, Jazz Pharmaceuticals, Merrimack Pharmaceuticals, Prometheus Laboratories, Inc., Sandoz Biopharmaceuticals, Taiho Oncology, and Tesaro* as new Corporate Members for 2016. *Biodesix, Onyx Pharmaceuticals, and Sargas Pharmaceutical Adherence & Compliance (SPAC) International* did not renew their memberships for 2016. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

Novartis Oncology informs ANCO that it is hosting virtual *ASCO Annual Meeting* sessions at www.asco2016.com.

Clinical Trial News

ASCO's Research Community Forum (formerly the *Community Research Forum*) is expanding to have a greater impact on research sites from all types of research settings. The *Forum* is inviting researchers and staff from all types of sites to participate in this unique venue with the aim to advance cancer research and support research program management. The *Forum's* annual meeting takes place at ASCO on September 25-26th. Please visit www.asco.org/research-community-forum to learn more.

Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- POLO Trial-A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease has not Progressed on First Line Platinum Based Therapy (PANC0018; cancer.stanford.edu/trials/list.html#studyId=NCT02184195). Principal Investigator: James Ford, MD; Contact: Kevin Morrison, (650) 725-5459, kmmorris@stanford.edu
- My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of these Agents [VAR0115; med.stanford.edu/cancer/trials/results.html?ctid=NCT02091141]. Principal Investigator: James

Ford, MD; Contact: Kevin Morrison, (650) 725-5459, kmmorris@stanford.edu

- A Randomized Multi-Center Study Comparing no Drainage to Preoperative Biliary Drainage using Metal Stents in Patients with Resectable Pancreatic or Periapillary Cancer [NCT01774019]. Principal Investigator: Brendan Visser, MD; Contact: Alifia Hasan, (650) 721-6509; alifia@stanford.edu

- A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors [NCT02576431]. Principal Investigator: Shivaani Kummar, MD, PhD; Contact: Rich Brotherton, (650) 723-3589; rbrother@stanford.edu

UC Davis brings the following clinical trial (not previously listed or changed) to the attention of the ANCO membership:

- Enzalutamide and Metformin Combination Therapy to Overcome Autophagy Resistance in Castration Resistant Prostate Cancer (UCDCCC#243/NCT029339168). Principal Investigator: Christopher Evans, M.D.; Contact: Anthony Martinez, (916) 734-0162

Publications, Resources, Services, & Surveys

ANCO and MOASC have partnered with SullivanLuallin Group to offer your practice the opportunity to participate in an Oncology-based *Patient Satisfaction Survey*. The Survey is designed to assess your organization's performance in key areas associated with the ACO and PQRS CAPHS Surveys. SullivanLuallin Group's eSurv: Online Patient Satisfaction Survey platform allows you to efficiently and cost-effectively capture how your patients feel about your systems, services, and performance. Download more information and an enrollment form at www.anco-online.org/PtSurvey2016.pdf.

ANCO and MOASC are jointly conducting a 2016 staff salary survey. The survey was e-mail/FAXed to all members in mid-May and is available online at www.anco-online.org/salsrvy.html. A \$50 Visa gift card for respondents is included in this year's survey. Return your completed survey no later than September 30th; results will be analyzed and reported in 4Q2016.

ASCO's CancerLinQ has launched a new website with expanded information and features for users to meet the needs of patients, practices, donors, researchers, and the larger oncology community. Visit www.CancerLinQ.org to learn more.

ASCO's Clinical Affairs Department is dedicated to providing services, education, and resources to

support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/asco-in-action/asco's-clinical-affairs-department-opens-new-survey-practice-operations.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to www.asco.org/PracticeNET for more information.

ASCO has issued a new guideline on the management of chronic pain in adult cancer survivors. The guideline provides clinicians with a broad range of pharmacologic and non-pharmacologic strategies for safe and effective treatment of persistent pain. Go to www.asco.org/practice-guidelines/quality-guidelines/guidelines/patient-and-survivor-care#/13021.

The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) have announced an open comment period for the revised evidence-based *Molecular Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors*. Learn more at amp.org/committees/clinical_practice/AMPclinicalpracticeguidelines/LBGOCF.cfm. The guideline is designed to provide state-of-the-art molecular testing of lung cancer recommendations. The comment period ends August 2nd.

The July 2016 issue of ASCO's *Journal of Oncology Practice* (JOP) is available online and features articles entitled *E-Mail Communication Practices and Preferences Among Patients and Providers in Large Comprehensive Cancer Center* and *Toxicity-Related Factors Associated with Use of Services Among Community Oncology Patients*. Visit jop.ascopubs.org for more information.

CMS has approved ASCO's *Quality Oncology Practice Initiative* (QOPI) as a qualified clinical data registry (QCDR), a pathway for oncologists to meet the agency's current quality reporting requirements. Oncology practices registered with QOPI will have the opportunity to fulfill CMS's PQRS or QCDR reporting requirements through QOPI. QOPI is designed to promote excellence in cancer care by helping oncologists create a culture of self-examination and improvement. ASCO offers the *QOPI Certification Program* to recognize QOPI participants who achieve rigorous standards for cancer care. The *QOPI Certification* designation can be used by certified practices to demonstrate an advanced commitment to quality and are eligible to receive a discount of up to 10% on medical malpractice rates from *The Doctors Company*, the nation's largest physician-owned medical malpractice insurer. Go to www.instituteforquality.org/qopi-qcp for more information.

The July/August issue of ACCC's *Oncology Issues* includes articles entitled *Engaging Patients & Assisting Primary Care Physicians in Lung Cancer Screening; Start Small, Think Big! Fusing Clinical & Business Metrics to Improve Quality & Effect Change*; and, *Prehab Improves Outcomes for Oncology Patients*. Visit www.accc-cancer.org/oncology_issues to read this issue.

ACCC's online *Oncology Drug Database* provides quick access to information on oncology drug coding, billing, and reimbursement at www.accc-cancer.org/drugdatabase/.

ACCC's enhanced set of *Financial Advocacy Network* resources are at www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp. This "one-stop" destination for comprehensive financial advocacy information includes online training materials, practical financial advocacy tools, peer-to-peer networking, and more.

ACCC's 2016 *Patient Assistance and Reimbursement Guide* is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. New for 2016 are tips for optimizing co-pay assistance programs and new financial advocate skills for the new healthcare environment. Visit [\[cancer.org/publications/pdf/Patient-Assistance-Guide-2016.pdf\]\(http://cancer.org/publications/pdf/Patient-Assistance-Guide-2016.pdf\) to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* \(FAN\) app is available at \[accc-fan-app.org\]\(http://accc-fan-app.org\). ASH also has a webpage \(at \[www.hematology.org/Clinicians/Drugs/Programs/\]\(http://www.hematology.org/Clinicians/Drugs/Programs/\)\) that provides a consolidated list of resources for hematologists and patients trying to access high cost hematologic drugs. And, at NCCN's Reimbursement Resource Room \(\[www.nccn.org/reimbursement_resource_room/default.asp\]\(http://www.nccn.org/reimbursement_resource_room/default.asp\)\) you can select a cancer diagnosis or supportive care indication and learn about reimbursement help and services available to you. Finally, *assistPoint* is your website for complimentary one-stop cancer Patient Assistance. You can search by generic, brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for 113 cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to \[www.assistpoint.com\]\(http://www.assistpoint.com\) to learn more.](http://www.accc-</p></div><div data-bbox=)

NCCN has updated their *Clinical Practice Guidelines in Oncology* and/or *Drugs & Biologics Compendium* for breast cancer screening and diagnosis (V1.2016), cancer-associated venous thromboembolic disease (V1.2016), central nervous system cancers (V1.2016), distress management (V2.2016), esophageal and esophagogastric cancer (V2.2016), gastric cancer (V2.2016), malignant pleural mesothelioma (V3.2016), melanoma (V3.2016), thymomas and thymic carcinomas (V3.2016), thyroid carcinoma (V1.2016), and very advanced head and neck cancer (V1.2016).